A phase II clinical trial of RPL-554 as an add-on therapy to short-acting bronchodilators and other commonly used therapies for the treatment of hospitalized patients with acute exacerbations of Chronic-obstructive-pulmonary-disease (COPD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ensifentrine (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use

Most Recent Events

10 Aug 2017 New trial record
08 Aug 2017 According to a Verona Pharma media release, the company is planning to initiate this study in the second half of 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight